Sanofi Takes Another Step Forward In MS, Files Lemtrada NDA
This article was originally published in Pharmaceutical Approvals Monthly
Sanofi is seeking a six-month priority review for the multiple sclerosis drug Lemtrada, positioning it for a potential launch by the end of the year. Meanwhile, FDA action on Aubagio is expected in June.
You may also be interested in...
Settling In To The “New Normal”: Midway Through 2012, Another Banner Year For Drug Approvals Is Within Reach
The forecast for 2012 approvals looks sunny. FDA approved almost as many novel drugs in the first half of 2012 as it did in the first half of its record-breaking 2011 – and the agency has more than twice as many pending NME applications with user fee goals in the next six months as it had last year.
Sanofi Sets Sights On Multiple Sclerosis Leadership
With the release of “unprecedented” data on its Phase III MS candidate alemtuzumab and its once-daily oral therapy teriflunomide already under regulatory review, Sanofi looks for a leadership role in the increasingly fragmented market it expects will approach $20 billion by 2016.
Sanofi/Genzyme MS Drug Lemtrada Scores High Against Rebif
Genzyme, a Sanofi company, set the bar high for its multiple sclerosis contender by stacking it up against Roche’s interferon beta-1a in Phase III trials and got the results it was looking for, with a filing set for this quarter.